You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 21, 2025

CLINICAL TRIALS PROFILE FOR AMPICILLIN SODIUM


✉ Email this page to a colleague

« Back to Dashboard


505(b)(2) Clinical Trials for Ampicillin Sodium

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
New Formulation NCT00244777 ↗ Introduction of Hypo-osmolar ORS for Routine Use Completed United States Agency for International Development (USAID) Phase 4 2002-12-01 The World Health Organization has very recently recommended the routine use of a hypo-osmolar ORS in the management of diarrhoeal diseases. This recommendation is based on the better efficacy of the hypo-osmolar ORS over the standard WHO ORS demonstrated in controlled clinical trials. The recommendation, however, also expressed the need for "careful monitoring to better assess risk, if any, of symptomatic hyponatraemia". There thus is a need for phase IV trials before the new solution is introduced into routine clinical practice to assess the risk in relatively large number of patient populations. The proposed study will be carried out at two different settings- at the urban settings of the Dhaka Hospital (60000 patients) and at the rural settings of the Matlab Hospital (15000 patients) of ICDDR,B. The hypo-osmolar rice or glucose-based ORS will be introduced as standard management of patients with diarrhoea . The hypo-osmolar ORS will contain 75 mmol /L of sodium instead of 90 mmol/L. Surveillance will be carried out to detect adverse events focusing on the occurrence of seizures or undue lethargy during hospitalization. Each episode of seizure or undue lethargy would be evaluated to determine if they are associated with abnormal levels of serum sodium or glucose, or fever. It has been estimated that about 3% (1,800) of patients initially admitted to the Short Stay Ward of the Dhaka Hospital, and 340 patients at the Matlab Hospital might require admission to the longer stay inpatient wards due to seizure or altered consciousness. Such patients would be thoroughly assessed including determination of their serum sodium and glucose, two common causes of seizures/altered consciousness, to determine if and to what extent they could be attributed to hyponatraemia.The results from this study would be used in planning and implementing the routine use of the new formulation of ORS at all Government, NGO and private health care facilities that treat diarrhoeal patients, in Bangladesh and in other countries.
New Formulation NCT00244777 ↗ Introduction of Hypo-osmolar ORS for Routine Use Completed International Centre for Diarrhoeal Disease Research, Bangladesh Phase 4 2002-12-01 The World Health Organization has very recently recommended the routine use of a hypo-osmolar ORS in the management of diarrhoeal diseases. This recommendation is based on the better efficacy of the hypo-osmolar ORS over the standard WHO ORS demonstrated in controlled clinical trials. The recommendation, however, also expressed the need for "careful monitoring to better assess risk, if any, of symptomatic hyponatraemia". There thus is a need for phase IV trials before the new solution is introduced into routine clinical practice to assess the risk in relatively large number of patient populations. The proposed study will be carried out at two different settings- at the urban settings of the Dhaka Hospital (60000 patients) and at the rural settings of the Matlab Hospital (15000 patients) of ICDDR,B. The hypo-osmolar rice or glucose-based ORS will be introduced as standard management of patients with diarrhoea . The hypo-osmolar ORS will contain 75 mmol /L of sodium instead of 90 mmol/L. Surveillance will be carried out to detect adverse events focusing on the occurrence of seizures or undue lethargy during hospitalization. Each episode of seizure or undue lethargy would be evaluated to determine if they are associated with abnormal levels of serum sodium or glucose, or fever. It has been estimated that about 3% (1,800) of patients initially admitted to the Short Stay Ward of the Dhaka Hospital, and 340 patients at the Matlab Hospital might require admission to the longer stay inpatient wards due to seizure or altered consciousness. Such patients would be thoroughly assessed including determination of their serum sodium and glucose, two common causes of seizures/altered consciousness, to determine if and to what extent they could be attributed to hyponatraemia.The results from this study would be used in planning and implementing the routine use of the new formulation of ORS at all Government, NGO and private health care facilities that treat diarrhoeal patients, in Bangladesh and in other countries.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for Ampicillin Sodium

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00002052 ↗ Prospective Comparison of Ampicillin / Amoxicillin Versus Ceftriaxone for the Treatment of Salmonella Infections in AIDS Patients Completed University of Southern California N/A 1969-12-31 To compare the effectiveness of standard treatment with parenteral ampicillin and oral amoxicillin compared to initial daily therapy with ceftriaxone followed by 3 times weekly suppressive treatment for salmonella infections in AIDS patients.
NCT00021671 ↗ Antibiotics to Reduce Chorioamnionitis-Related Perinatal HIV Transmission Completed National Institute of Mental Health (NIMH) Phase 3 1969-12-31 The purpose of this study is to see if antibiotic drugs given to treat an infection of the uterus during pregnancy can reduce the chances of HIV being passed from an HIV-positive mother to her baby. A link between bacterial disease of the vagina, premature birth, infection of the uterus during pregnancy, and the passing of HIV from a mother to her baby has been found. Early treatment of these problems may reduce the risk of passing HIV from an HIV-positive mother to her baby. [Note: As of 02/21/03, enrollment into this study was halted because preliminary data showed that the study antibiotics were not effective in preventing mother-to-child HIV transmission.]
NCT00021671 ↗ Antibiotics to Reduce Chorioamnionitis-Related Perinatal HIV Transmission Completed National Institute on Drug Abuse (NIDA) Phase 3 1969-12-31 The purpose of this study is to see if antibiotic drugs given to treat an infection of the uterus during pregnancy can reduce the chances of HIV being passed from an HIV-positive mother to her baby. A link between bacterial disease of the vagina, premature birth, infection of the uterus during pregnancy, and the passing of HIV from a mother to her baby has been found. Early treatment of these problems may reduce the risk of passing HIV from an HIV-positive mother to her baby. [Note: As of 02/21/03, enrollment into this study was halted because preliminary data showed that the study antibiotics were not effective in preventing mother-to-child HIV transmission.]
NCT00021671 ↗ Antibiotics to Reduce Chorioamnionitis-Related Perinatal HIV Transmission Completed National Institute of Allergy and Infectious Diseases (NIAID) Phase 3 1969-12-31 The purpose of this study is to see if antibiotic drugs given to treat an infection of the uterus during pregnancy can reduce the chances of HIV being passed from an HIV-positive mother to her baby. A link between bacterial disease of the vagina, premature birth, infection of the uterus during pregnancy, and the passing of HIV from a mother to her baby has been found. Early treatment of these problems may reduce the risk of passing HIV from an HIV-positive mother to her baby. [Note: As of 02/21/03, enrollment into this study was halted because preliminary data showed that the study antibiotics were not effective in preventing mother-to-child HIV transmission.]
NCT00137501 ↗ Two Dose Regimens of Nifedipine for the Management of Preterm Labor Terminated American University of Beirut Medical Center Phase 3 2003-05-01 Preterm birth is one of the most important causes of perinatal morbidity and mortality worldwide. Prevention and treatment of preterm labor is important, not as an end in itself, but as a means of reducing adverse events for the neonate. A wide range of tocolytics, drugs used to suppress uterine contractions, have been tried. Magnesium sulfate (MgSO4) is the most widely used tocolytic at the American University of Beirut Medical Center despite the fact that an effective tocolytic role of MgSO4 has never been established. Moreover, the currently available data are suggestive of deleterious fetal effects of MgSO4 in the setting of preterm labor to the extent that some authorities are recommending abandoning it for routine use as a tocolytic therapy. Calcium channel blockers have the ability to inhibit contractility in smooth muscle cells. Consequently, nifedipine has emerged as an effective and rather safe alternative tocolytic agent for the management of preterm labor after several studies have shown that the use of nifedipine in comparison with other tocolytics is associated with a more frequent successful prolongation of pregnancy, resulting in significantly fewer admissions of newborns to the neonatal intensive care unit, and is associated with a lower incidence of respiratory distress syndrome. The unequivocal impact of this method of tocolysis on short term postponement of delivery and the opportunity that this provides for affecting in-utero transfer and steroid administration has prompted many investigators to recommend focusing future trials on testing different dose regimens of nifedipine. To the best of the investigators' knowledge, no study comparing two different dose regimens of nifedipine has been previously published in the literature. The objective of their study is to compare the effectiveness of a high versus a low dose regimen in a total of 200 patients admitted with the diagnosis of preterm labor between 24 and 34 weeks of gestation. In addition, the investigators' study will try to assess the safety profile of the 2 dose regimens on the mother and the neonate by assessing a selected number of outcome variables. The data generated will be used to change their protocol for managing patients presenting with threatened preterm delivery and will fill the existing gap regarding the most effective and safest dose regimen of nifedipine in such patients.
NCT00244777 ↗ Introduction of Hypo-osmolar ORS for Routine Use Completed United States Agency for International Development (USAID) Phase 4 2002-12-01 The World Health Organization has very recently recommended the routine use of a hypo-osmolar ORS in the management of diarrhoeal diseases. This recommendation is based on the better efficacy of the hypo-osmolar ORS over the standard WHO ORS demonstrated in controlled clinical trials. The recommendation, however, also expressed the need for "careful monitoring to better assess risk, if any, of symptomatic hyponatraemia". There thus is a need for phase IV trials before the new solution is introduced into routine clinical practice to assess the risk in relatively large number of patient populations. The proposed study will be carried out at two different settings- at the urban settings of the Dhaka Hospital (60000 patients) and at the rural settings of the Matlab Hospital (15000 patients) of ICDDR,B. The hypo-osmolar rice or glucose-based ORS will be introduced as standard management of patients with diarrhoea . The hypo-osmolar ORS will contain 75 mmol /L of sodium instead of 90 mmol/L. Surveillance will be carried out to detect adverse events focusing on the occurrence of seizures or undue lethargy during hospitalization. Each episode of seizure or undue lethargy would be evaluated to determine if they are associated with abnormal levels of serum sodium or glucose, or fever. It has been estimated that about 3% (1,800) of patients initially admitted to the Short Stay Ward of the Dhaka Hospital, and 340 patients at the Matlab Hospital might require admission to the longer stay inpatient wards due to seizure or altered consciousness. Such patients would be thoroughly assessed including determination of their serum sodium and glucose, two common causes of seizures/altered consciousness, to determine if and to what extent they could be attributed to hyponatraemia.The results from this study would be used in planning and implementing the routine use of the new formulation of ORS at all Government, NGO and private health care facilities that treat diarrhoeal patients, in Bangladesh and in other countries.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Ampicillin Sodium

Condition Name

Condition Name for Ampicillin Sodium
Intervention Trials
Diarrhoea 2
HIV Infections 2
Severe Malnutrition 1
Atrial Fibrillation 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Ampicillin Sodium
Intervention Trials
HIV Infections 2
Diarrhea 2
Communicable Diseases 2
Infections 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Ampicillin Sodium

Trials by Country

Trials by Country for Ampicillin Sodium
Location Trials
Japan 15
United States 3
Bangladesh 2
Korea, Republic of 1
Brazil 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Ampicillin Sodium
Location Trials
Texas 1
North Carolina 1
California 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Ampicillin Sodium

Clinical Trial Phase

Clinical Trial Phase for Ampicillin Sodium
Clinical Trial Phase Trials
Phase 4 2
Phase 3 5
Phase 2 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Ampicillin Sodium
Clinical Trial Phase Trials
Completed 8
Unknown status 1
Not yet recruiting 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Ampicillin Sodium

Sponsor Name

Sponsor Name for Ampicillin Sodium
Sponsor Trials
International Centre for Diarrhoeal Disease Research, Bangladesh 2
Chiesi Farmaceutici S.p.A. 1
PENTA Foundation 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Ampicillin Sodium
Sponsor Trials
Other 12
NIH 3
Industry 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Ampicillin Sodium: Clinical Trials, Market Analysis, and Projections

Introduction to Ampicillin Sodium

Ampicillin sodium, a member of the extended-spectrum β-lactam family, is a broad-spectrum antibiotic similar in structure to penicillin. It is widely used in the treatment of various bacterial infections, including those caused by gram-negative and gram-positive bacteria.

Mechanism of Action

Ampicillin sodium works by inhibiting the synthesis of bacterial cell walls, specifically targeting penicillin-binding proteins (PBPs). This action weakens the bacterial cell wall, leading to cytolysis and the death of the bacteria. Its bactericidal action is most effective against bacteria in the stage of active multiplication[4].

Clinical Uses and Indications

Ampicillin sodium is prescribed for a range of infections, including respiratory, urinary, meningoencephalitis, and gastrointestinal diseases. It is effective against many gram-negative bacterial strains, such as Shigella and Salmonella, as well as certain gram-positive bacteria like Staphylococcus and Streptococcus species. It is also used against some vancomycin-resistant Enterococcus species[1][2][4].

Clinical Trials and Efficacy

Clinical trials and antimicrobial susceptibility tests (ASTs) are crucial in determining the efficacy of ampicillin sodium against various bacterial species. These tests help in identifying the susceptibility of bacteria to ampicillin, thereby guiding clinical decisions on antibiotic prescriptions. However, specific details on ongoing or recent clinical trials for ampicillin sodium are not widely available in the public domain, as this information is often confined to scientific literature and clinical trial registries.

Market Analysis

Market Size and Growth Projections

The global ampicillin market is anticipated to experience significant growth. By 2024, the market is expected to reach USD 388.1 million and is projected to further increase to USD 480.1 million by 2033, with a Compound Annual Growth Rate (CAGR) of 2.4% during the forecast period[2].

Another report suggests that the market size could reach $385.82 million by 2030, growing at a CAGR of 3.5% from 2023 to 2030[3].

Market Segments

  • Type Segment: Ampicillin sodium for injection is expected to dominate due to its instantaneous action via intravenous administration[2].
  • Mode of Administration: Oral administration is projected to be the most popular, capturing a significant market share due to its convenience and non-invasiveness[2].
  • Disease Indication: Infections are the primary indication, as ampicillin effectively treats a range of bacterial infections[2].
  • Distribution Channel: Hospital pharmacies are anticipated to lead with a substantial market share, around 64.9%[2].

Growth Drivers and Opportunities

The increasing incidence of infectious diseases and advancements in pharmaceutical manufacturing are key drivers for the ampicillin market. Emerging markets in Asia-Pacific and Latin America present significant growth opportunities due to increased healthcare spending, more healthcare facilities, and greater awareness of infectious diseases[2][3].

Competitive Landscape

The competitive landscape of the ampicillin market involves several pharmaceutical companies and research institutions. Collaborations and partnerships between these entities are expected to foster innovation and market expansion. Companies like Thermo Fisher Scientific Inc. are investing heavily in research and development to enhance bioprocessing capabilities and ensure a reliable supply of ampicillin[3].

Market Projections for Ampicillin Sodium API

The Ampicillin Sodium API market is also expected to see substantial growth. Valued at USD 0.23 billion in 2023, it is projected to reach USD 0.39 billion by 2031, growing at a CAGR of 6.5% from 2025 to 2031. This market is segmented based on type (purity ≥99%, purity <99%) and application (injection, others), with geographical regions also playing a significant role[5].

Regulatory and Resistance Considerations

The widespread use of antibiotics, including ampicillin, has led to concerns about antibiotic resistance. Regulatory oversight by organizations like the WHO and CDC influences market growth and emphasizes the need for responsible antibiotic use. The presence of extended-spectrum β-lactamases (ESBLs) in some bacterial strains complicates the use of β-lactam antibiotics like ampicillin, highlighting the need for continuous monitoring and adaptation in treatment strategies[1][2].

Conclusion

Ampicillin sodium remains a vital antibiotic in the treatment of various bacterial infections. With projected market growth driven by increasing infectious disease incidence and advancements in pharmaceutical manufacturing, it is clear that ampicillin will continue to play a significant role in healthcare.

Key Takeaways

  • Mechanism of Action: Ampicillin sodium inhibits bacterial cell wall synthesis.
  • Clinical Uses: Effective against a broad range of bacterial infections.
  • Market Growth: Projected to reach USD 480.1 million by 2033 with a CAGR of 2.4%.
  • Growth Drivers: Increasing infectious disease incidence and pharmaceutical advancements.
  • Emerging Markets: Asia-Pacific and Latin America offer significant growth opportunities.
  • Regulatory Considerations: Antibiotic resistance and regulatory oversight are crucial factors.

FAQs

What is the mechanism of action of ampicillin sodium?

Ampicillin sodium works by inhibiting the synthesis of bacterial cell walls, specifically targeting penicillin-binding proteins (PBPs), which leads to the death of the bacteria.

What are the common indications for ampicillin sodium?

Ampicillin sodium is prescribed for respiratory, urinary, meningoencephalitis, and gastrointestinal diseases caused by susceptible bacteria.

How is the ampicillin market expected to grow?

The global ampicillin market is expected to reach USD 480.1 million by 2033, growing at a CAGR of 2.4% from 2024 to 2033.

What are the key growth drivers for the ampicillin market?

The increasing incidence of infectious diseases and advancements in pharmaceutical manufacturing are key drivers for the ampicillin market.

Which regions offer significant growth opportunities for the ampicillin market?

Emerging markets in Asia-Pacific and Latin America present significant growth opportunities due to increased healthcare spending and greater awareness of infectious diseases.

Sources

  1. GoldBio, "Ampicillin (Sodium), USP Grade - GoldBio"
  2. GlobeNewswire, "Ampicillin Market Is Expected To Reach A Revenue Of USD 480.1 Mn By 2033 At 2.4 CAGR - Insights by Dimension Market Research"
  3. IndustryARC, "Ampicillin Market - Forecast, 2024-2030"
  4. EMPR, "Ampicillin Sodium Injection Prescription & Dosage Information - MPR"
  5. Market Research Intellect, "Ampicillin Sodium API Market Size and Projections"

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.